Skip to main content
Article thumbnail
Location of Repository

Inhibition of cathepsin B activity attenuates extracellular matrix degradation and inflammatory breast cancer invasion

By Bernadette C Victor, Arulselvi Anbalagan, Mona M Mohamed, Bonnie F Sloane and Dora Cavallo-Medved
Topics: Research Article
Publisher: BioMed Central
OAI identifier:
Provided by: PubMed Central

Suggested articles


  1. (1985). A cellular binding site for the Mr 55,000 form of the human plasminogen activator, urokinase.
  2. (2008). are associated with breast cancer basal-like and triple-negative immunophenotype.
  3. (2011). BF: Cathepsin B: a potential prognostic marker for inflammatory breast cancer.
  4. (2005). BF: Caveolin-1 mediates the expression and localization of cathepsin B, pro-urokinase plasminogen activator and their cell-surface receptors in human colorectal carcinoma cells.
  5. (2000). BF: Human procathepsin B interacts with the annexin II tetramer on the surface of tumor cells.
  6. (1992). BF: Human tumour cathepsin B. Comparison with normal liver cathepsin B. Biochem J
  7. (2009). BF: Imaging and quantifying the dynamics of tumor-associated proteolysis. Clin Exp Metastasis
  8. (2000). BF: Imaging proteolysis by living human breast cancer cells. Neoplasia
  9. (2009). BF: Live-cell imaging demonstrates extracellular matrix degradation in association with active cathepsin B in caveolae of endothelial cells during tube formation. Exp Cell Res
  10. (2011). BF: Live-cell imaging of tumor proteolysis: Impact of cellular and non-cellular microenvironment. Biochim Biophys Acta
  11. (2003). BF: Mutant K-ras regulates cathepsin B localization on the surface of human colorectal carcinoma cells. Neoplasia
  12. (1994). BF: Pericellular pH affects distribution and secretion of cathepsin B in malignant cells. Cancer Res
  13. (2008). BF: Visualizing protease activity in living cells: from two dimensions to four dimensions. Curr Protoc Cell Biol
  14. (1995). BM: The urokinase-type plasminogen activator receptor, a GPI-linked protein, is localized in caveolae.
  15. (2005). Brugge JS: Modelling glandular epithelial cancers in threedimensional cultures. Nat Rev Cancer
  16. (2005). Cathepsin B and tumor proteolysis: contribution of the tumor microenvironment. Semin Cancer Biol
  17. (2011). Cathepsin B and uPAR knockdown inhibits tumor-induced angiogenesis by modulating VEGF expression in glioma. Cancer Gene Ther
  18. (1999). Chapman HA: A role for caveolin and the urokinase receptor in integrin-mediated adhesion and signaling.
  19. (2001). CL: Transgenic polyoma middle-T mice model premalignant mammary disease. Cancer Res
  20. (2005). Distinct molecular signature of inflammatory breast cancer by cDNA microarray analysis. Breast Cancer Res Treat
  21. (1999). Ethier SP: Molecular cytogenetic analysis of 11 new breast cancer cell lines.
  22. (2001). Expression of the urokinase-type plasminogen activator receptor in human articular chondrocytes: association with caveolin and beta 1-integrin. Histochem Cell Biol
  23. (1986). F: Binding of single-chain prourokinase to the urokinase receptor of human U937 cells.
  24. (2003). Family C1 cysteine proteases: biological diversity or redundancy? Biol Chem
  25. (1998). Finberg RW: Determination of the non-ionic detergent insolubility and phosphoprotein associations of glycosylphosphatidylinositol-anchored proteins expressed on T cells.
  26. (2004). Gilad E: CD44 interaction with Na+-H+ exchanger (NHE1) creates acidic microenvironments leading to hyaluronidase-2 and cathepsin B activation and breast tumor cell invasion.
  27. (1991). Graeff H: Cathepsin B efficiently activates the soluble and the tumor cell receptor-bound form of the proenzyme urokinase-type plasminogen activator (Pro-uPA).
  28. (2008). Henrique-Silva F: Inhibitory effect of the sugarcane cystatin CaneCPI-4 on cathepsins B and L and human breast cancer cell invasion. Biol Chem
  29. (1975). Hursting SD: Inflammatory breast carcinoma incidence and survival: the surveillance, epidemiology, and Victor
  30. (2009). Inflammatory breast carcinoma as a model of accelerated self-metastatic expansion by intravascular growth.
  31. (2011). International expert panel on inflammatory breast cancer: consensus statement for standardized diagnosis and treatment. Ann Oncol
  32. (2001). Invasion activating caveolin-1 mutation in human scirrhous breast cancers. Cancer Res
  33. (2004). JS: RNAi-mediated inhibition of cathepsin B and uPAR leads to decreased cell invasion, angiogenesis and tumor growth in gliomas. Oncogene
  34. (1991). Katunuma N: Novel epoxysuccinyl peptides. Selective inhibitors of cathepsin B, in vitro.
  35. (2006). KL: Overexpression of caveolin-1 and -2 in cell lines and in human samples of inflammatory breast cancer. Breast Cancer Res Treat
  36. (2009). Le Guennec JY: Voltage-gated sodium channel activity promotes cysteine cathepsin-dependent invasiveness and colony growth of human cancer cells.
  37. (2001). MC: Cell biology of caveolae and caveolin. Adv Drug Deliv Rev
  38. (2010). Merajver SD: Characterization of the roles of RHOC and RHOA GTPases in invasion, motility, and matrix adhesion in inflammatory and aggressive breast cancers. Cancer
  39. (2004). Merajver SD: WISP3 and RhoC guanosine triphosphatase cooperate in the development of inflammatory breast cancer. Breast Cancer Res
  40. (2009). MP: Caveolin-1 (P132L), a common breast cancer mutation, confers mammary cell invasiveness and defines a novel stem cell/metastasisassociated gene signature.
  41. (2008). Nabi IR: Phosphorylated caveolin-1 regulates Rho/ROCK-dependent focal adhesion dynamics and tumor cell migration and invasion. Cancer Res
  42. (2004). Pestell RG: Caveolin-1 in breast cancer. Cancer Biol Ther
  43. (2002). Phorbol ester activation of a proteolytic cascade capable of activating latent transforming growth factor-betaL a process initiated by the exocytosis of cathepsin B.
  44. (1995). Piana L: Inflammatory carcinomas of the breast: a clinical, pathological, or a clinical and pathological definition?
  45. (2010). Rao JS: Co-depletion of cathepsin B and uPAR induces G0/G1 arrest in glioma via FOXO3a mediated p27 upregulation. PLoS One
  46. (2008). Reinheckel T: Reduced tumour cell proliferation and delayed development of high-grade mammary carcinomas in cathepsin B-deficient mice. Oncogene
  47. (2006). Reinheckel T: Tumor cell-derived and macrophage-derived cathepsin B promotes progression and lung metastasis of mammary cancer. Cancer Res
  48. (2009). RJ: Bicarbonate increases tumor pH and inhibits spontaneous metastases. Cancer Res
  49. (2010). S: Breast cancer stem-like cells are inhibited by a non-toxic aryl hydrocarbon receptor agonist. PLoS One
  50. (1999). SH: A novel human xenograft model of inflammatory breast cancer. Cancer Res
  51. (2003). Sloane BF: Cell-surface cathepsin B: understanding its functional significance. Curr Top Dev Biol
  52. (2006). Sloane BF: Cysteine cathepsins: multifunctional enzymes in cancer. Nat Rev Cancer
  53. (2010). Targeting MMP-9, uPAR, and cathepsin B inhibits invasion, migration and activates apoptosis in prostate cancer cells. Cancer Gene Ther
  54. (1993). Terao T: Effects of membrane-associated cathepsin B on the activation of receptorbound prourokinase and subsequent invasion of reconstituted basement membranes. Biochim Biophys Acta
  55. (1992). Terao T: Inhibition of in vitro ovarian cancer cell invasion by modulation of urokinase-type plasminogen activator and cathepsin B. Cancer Res
  56. (1994). The annexin II2p11(2) complex is the major protein component of the triton X-100-insoluble low-density fraction prepared from MDCK cells in the presence of Ca2+. Biochim Biophys Acta
  57. (2008). The cancer degradome: proteases and cancer biology.Edited by: Dylan Edwards, Francesco Blasi, Gunilla Hoyer-Hansen, Bonnie Sloane.
  58. (2005). Turk V: Carboxypeptidases cathepsins × and B display distinct protein profile in human cells and tissues. Exp Cell Res
  59. (2008). Unraveling the microenvironmental influences on the normal mammary gland and breast cancer. Semin Cancer Biol

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.